After a Setback, What’s Next for Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical focused on creating novel therapies for treatment of cancer, announced that a crucial phase 3 trial of QINLOCK in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib did not meet the primary endpoint of improved...
